Raşit Kılıç1, Tongabay Cumurcu2, Enver Sancaktar3, Osman Evliyaoğlu4, Hafize Sezer5. 1. a Department of Ophthalmology , Sivas Numune Hospital , Sivas , Turkey . 2. b Department of Ophthalmology , Inonu University Faculty of Medicine , Malatya , Turkey . 3. c Department of Biochemistry , Cumhuriyet University Faculty of Medicine , Sivas , Turkey . 4. d Department of Biochemistry , Dicle University Faculty of Medicine , Diyarbakır , Turkey and. 5. e Department of Biostatistics , Cumhuriyet University Faculty of Medicine , Sivas , Turkey.
Abstract
AIM: Our aim was to evaluate the serum prolidase activity, total antioxidant capacity (TAC) and total oxidant status (TOS) in patients with keratoconus. MATERIAL AND METHOD: A total 69 keratoconus patients and 72 control subjects with similar age and gender were evaluated within the scope of this study. The keratoconus group was divided into four stages with the modified Krumeich classification. Serum prolidase activity, TAC and TOS were measured and compared between the patient and control groups. RESULTS: The median serum prolidase enzyme activity value was 528.3 (684.1-416.7) U/L in the keratoconus group and 606.2 (812.9-482.3) U/L in the control group. The difference between the groups was statistically significant (p = 0.027). The median TAC value was 1.24 (1.37-1.05) mmol/L in the keratoconus group and 1.29 (1.38-1.18) mmol/L in the control group. The median TOS value was 2 (4-1) μmol/L in the keratoconus group and 3 (4-2) μmol/L in the control group. There was no statistically significant difference between the two groups in terms of TAC or TOS (p = 0.113 and p = 0.366, respectively). There was a positive correlation between TAC and TOS in keratoconus group but not in the control group (r = 0.670, p = 0.001 and r = 0.141, p = 0.241, respectively). No significant relationship was seen between the keratoconus group stages and serum prolidase activity, TAS or TOS (p = 0.894, p = 0.155 and p = 0.381, respectively). CONCLUSION: In conclusion, a significant relationship was found between decreased serum prolidase activity and keratoconus but there was no significant relationship between keratoconus and serum TAC or TOS.
AIM: Our aim was to evaluate the serum prolidase activity, total antioxidant capacity (TAC) and total oxidant status (TOS) in patients with keratoconus. MATERIAL AND METHOD: A total 69 keratoconus patients and 72 control subjects with similar age and gender were evaluated within the scope of this study. The keratoconus group was divided into four stages with the modified Krumeich classification. Serum prolidase activity, TAC and TOS were measured and compared between the patient and control groups. RESULTS: The median serum prolidase enzyme activity value was 528.3 (684.1-416.7) U/L in the keratoconus group and 606.2 (812.9-482.3) U/L in the control group. The difference between the groups was statistically significant (p = 0.027). The median TAC value was 1.24 (1.37-1.05) mmol/L in the keratoconus group and 1.29 (1.38-1.18) mmol/L in the control group. The median TOS value was 2 (4-1) μmol/L in the keratoconus group and 3 (4-2) μmol/L in the control group. There was no statistically significant difference between the two groups in terms of TAC or TOS (p = 0.113 and p = 0.366, respectively). There was a positive correlation between TAC and TOS in keratoconus group but not in the control group (r = 0.670, p = 0.001 and r = 0.141, p = 0.241, respectively). No significant relationship was seen between the keratoconus group stages and serum prolidase activity, TAS or TOS (p = 0.894, p = 0.155 and p = 0.381, respectively). CONCLUSION: In conclusion, a significant relationship was found between decreased serum prolidase activity and keratoconus but there was no significant relationship between keratoconus and serum TAC or TOS.
Entities:
Keywords:
Keratoconus; oxidative stress; prolidase activity; total antioxidant capacity; total oxidant status
Authors: Shari R Atilano; Daniel H Lee; Paula S Fukuhara; Marilyn Chwa; Anthony B Nesburn; Nitin Udar; M Cristina Kenney Journal: J Ophthalmic Vis Res Date: 2019 Jan-Mar